Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 13/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8086157 | 0.86 | CACNA1B (0.49) | HPGDHTTCACNA1BMAPTCACNA1C | |
| SCHEMBL3765021 | 0.86 | HPGD (0.47) | HPGDHTTCACNA1BMAPTCACNA1C | |
| SCHEMBL8082563 | 0.84 | CACNA1B (0.48) | HPGDHTTCACNA1BMAPTCACNA1C | |
| SCHEMBL13002406 | 0.80 | CACNA1B (0.51) | HPGDCACNA1BCACNA1CGAANR1I2 | |
| SCHEMBL13291497 | 0.80 | CACNA1B (0.49) | HPGDCACNA1BGAANR1I2 | |
| SCHEMBL8083318 | 0.80 | CACNA1B (0.46) | HPGDHTTCACNA1BCACNA1CGAA | |
| SCHEMBL3485159 | 0.79 | CACNA1B (0.50) | HPGDCACNA1BCACNA1CGAANR1I2 | |
| SCHEMBL8236293 | 0.79 | CACNA1B (0.51) | HPGDCACNA1BGAANR1I2 | |
| SCHEMBL13543317 | 0.79 | GAA (0.50) | HPGDCACNA1BCACNA1CGAANR1I2 | |
| SCHEMBL13932863 | 0.79 | HPGD (0.52) | HPGDHTTCACNA1BGAANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | claimed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | claimed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | claimed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | disclosed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | disclosed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | disclosed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1B | HPGD 1358/4885HTT 1751/4885CACNA1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.